CYP3A4 and myopathy: After discontinuation of the two drugs, the patient's CK returned to normal.<h4>Conclusion</h4>Almonertinib is a moderately sensitive substrate of CYP3A4, thereby may elevate statin concentration and increase the likelihood of developing myopathy.